Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity
2019 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Lyndon, Gavin J., Rita Prieto, Dalia B. Wajsbrot, Christer Allgulander, and Borwin Bandelow. "Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity." International Clinical Psychopharmacology 34, no. 3 (2019): 110-118. https://doi.org/10.1097/YIC.0000000000000256.
Documents & Media
Details
- Authors
- Lyndon, Gavin J.; Prieto, Rita; Wajsbrot, Dalia B.; Allgulander, Christer; Bandelow, Borwin
- Abstract
- Effects of baseline anxiety on the efficacy of venlafaxine extended release versus placebo were examined in a post hoc pooled subgroup analysis of 1573 patients enrolled in eight short-term studies of major depressive disorder. Anxiety subgroups were defined based on baseline 17-item Hamilton Rating Scale for Depression Item 10 score <3 (low) versus ≥3 (high). Change from baseline to final visit in Montgomery-Åsberg Depression Rating Scale total score and Montgomery-Åsberg Depression Rating Scale response and remission rates were analyzed. Change from baseline in Montgomery-Åsberg Depression Rating Scale total score and response and remission rates was significantly greater for venlafaxine extended release versus placebo in both low and high anxiety subgroups (all P < 0.0001). A statistically significant baseline anxiety by treatment interaction was observed for Montgomery-Åsberg Depression Rating Scale total score only (P = 0.0152). The adjusted mean change from baseline in Montgomery-Åsberg Depression Rating Scale total score was significantly greater in the high anxiety subgroup versus low anxiety subgroup for patients treated with venlafaxine extended release (-6.27 versus -3.89; P = 0.0440) but not placebo. These results support the efficacy of venlafaxine extended release for major depressive disorder treatment in patients with anxiety symptoms.
- Issue Date
- 2019
- Journal
- International Clinical Psychopharmacology
- Organization
- Universitätsmedizin Göttingen
- ISSN
- 1473-5857; 0268-1315
- Language
- English